Investments
200Portfolio Exits
50Funds
13Partners & Customers
2Service Providers
1
Want to inform investors similar to EQT Life Sciences about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest EQT Life Sciences News
Jan 12, 2023
美国心脏疾病医疗器械研发商，完成3500万美元D轮融资，投资方为Horizon 3 Healthcare等领投，Arboretum Ventures、Hostplus、EQT Life Sciences、Lumira Ventures、M. H. Carnegie Co跟投。
EQT Life Sciences Investments
200 Investments
EQT Life Sciences has made 200 investments. Their latest investment was in Amolyt Pharma as part of their Series C on January 1, 2023.
EQT Life Sciences Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
1/6/2023 | Series C | Amolyt Pharma | $138.38M | No | Andera Partners, ATEM Capital, Bpifrance, Credit Agricole Creation, CTI Life Sciences Fund, EQT Life Sciences, ICG, InnoBio, Kurma Partners, Mass General Brigham Ventures, Novo Holdings, OrbiMed Advisors, Pontifax, Relyens, Sectoral Asset Management, Sham Innovation Santé, Sofinnova Partners, Tekla Capital Management, and Turenne Group | 7 |
1/5/2023 | Series D | Cardiac Dimensions | $35M | No | Arboretum Ventures, EQT Life Sciences, Horizon 3 Healthcare, Hostplus, Lumira Ventures, M.H. Carnegie & Co., and Undisclosed Investors | 8 |
8/23/2022 | Series B - II | eTheRNA | $38.92M | No | China Grand Pharmaceutical & Healthcare, EQT Life Sciences, Fund+, Kenneth Chien, Marijn Dekkers, Novalis LifeSciences, Omega Funds, PMV, and Undisclosed Investors | 6 |
6/13/2022 | Series C | |||||
4/1/2022 | Series B - II |
Date | 1/6/2023 | 1/5/2023 | 8/23/2022 | 6/13/2022 | 4/1/2022 |
|---|---|---|---|---|---|
Round | Series C | Series D | Series B - II | Series C | Series B - II |
Company | Amolyt Pharma | Cardiac Dimensions | eTheRNA | ||
Amount | $138.38M | $35M | $38.92M | ||
New? | No | No | No | ||
Co-Investors | Andera Partners, ATEM Capital, Bpifrance, Credit Agricole Creation, CTI Life Sciences Fund, EQT Life Sciences, ICG, InnoBio, Kurma Partners, Mass General Brigham Ventures, Novo Holdings, OrbiMed Advisors, Pontifax, Relyens, Sectoral Asset Management, Sham Innovation Santé, Sofinnova Partners, Tekla Capital Management, and Turenne Group | Arboretum Ventures, EQT Life Sciences, Horizon 3 Healthcare, Hostplus, Lumira Ventures, M.H. Carnegie & Co., and Undisclosed Investors | China Grand Pharmaceutical & Healthcare, EQT Life Sciences, Fund+, Kenneth Chien, Marijn Dekkers, Novalis LifeSciences, Omega Funds, PMV, and Undisclosed Investors | ||
Sources | 7 | 8 | 6 |
EQT Life Sciences Portfolio Exits
50 Portfolio Exits
EQT Life Sciences has 50 portfolio exits. Their latest portfolio exit was New Amsterdam Pharma on November 22, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
11/22/2022 | Reverse Merger | 4 | |||
10/21/2021 | IPO | Public | 3 | ||
2/24/2021 | Acquired | 4 | |||
Date | 11/22/2022 | 10/21/2021 | 2/24/2021 | ||
|---|---|---|---|---|---|
Exit | Reverse Merger | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 4 | 3 | 4 |
EQT Life Sciences Fund History
13 Fund Histories
EQT Life Sciences has 13 funds, including LSP 7.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
2/11/2022 | LSP 7 | $1,140M | 2 | ||
3/10/2020 | LSP 6 | Multi-Stage Venture Capital | Closed | $600M | 2 |
12/12/2017 | LSP Health Economics Fund II | Late-Stage Venture Capital | Closed | $330M | 2 |
6/2/2016 | Life Sciences Partners V | ||||
3/10/2014 | Health Economics Fund |
Closing Date | 2/11/2022 | 3/10/2020 | 12/12/2017 | 6/2/2016 | 3/10/2014 |
|---|---|---|---|---|---|
Fund | LSP 7 | LSP 6 | LSP Health Economics Fund II | Life Sciences Partners V | Health Economics Fund |
Fund Type | Multi-Stage Venture Capital | Late-Stage Venture Capital | |||
Status | Closed | Closed | |||
Amount | $1,140M | $600M | $330M | ||
Sources | 2 | 2 | 2 |
EQT Life Sciences Partners & Customers
2 Partners and customers
EQT Life Sciences has 2 strategic partners and customers. EQT Life Sciences recently partnered with EQT Partners on November 11, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
11/10/2021 | Partner | Sweden | LSP and EQT join forces in healthcare investing The life science industry is going through a phase of unprecedented innovation and , through the partnership with LSP , EQT AB will be able to participate in this growth opportunity and open up doors for attractive new investments in the space . '' | 1 | |
11/24/2015 | Partner |
Date | 11/10/2021 | 11/24/2015 |
|---|---|---|
Type | Partner | Partner |
Business Partner | ||
Country | Sweden | |
News Snippet | LSP and EQT join forces in healthcare investing The life science industry is going through a phase of unprecedented innovation and , through the partnership with LSP , EQT AB will be able to participate in this growth opportunity and open up doors for attractive new investments in the space . '' | |
Sources | 1 |
EQT Life Sciences Service Providers
1 Service Provider
EQT Life Sciences has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Series A | Counsel | General Counsel |
Service Provider | |
|---|---|
Associated Rounds | Series A |
Provider Type | Counsel |
Service Type | General Counsel |
Partnership data by VentureSource
EQT Life Sciences Team
18 Team Members
EQT Life Sciences has 18 team members, including current Founder, Owner, Martijn Keijwegt.
Name | Work History | Title | Status |
|---|---|---|---|
Martijn Keijwegt | Founder, Owner | Current | |
Name | Martijn Keijwegt | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Founder, Owner | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.